033270.KS
Korea United Pharm Inc.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 18,470.00
+1.15%Year over year
Reported trailing growth
- Revenue
- +4.1%
- EBITDA
- +14.9%
- EBIT
- -4.3%
- EPS
- +116.2%
- Free cash flow
- +8993.7%
- Operating cash flow
- +351.4%
Forward estimates
Based on analyst estimates
- Revenue
- -48.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.2%
- EBITDA
- -0.7%
- EBIT
- +0.5%
- Net income
- -5.4%
- EPS
- -5.1%
- Free cash flow
- -11.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026